

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SIX MONTHS 2023 ACTUAL vs. 2022 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	MedTech	Total
WW As Reported	6.4%	3.7%	10.1%	6.0%
U.S.	8.6%	7.6%	15.5%	10.0%
International	4.7%	(0.7)%	5.2%	2.0%
WW Currency	(3.1)	(1.8)	(2.7)	(2.2)
U.S.	-	-	-	-
International	(5.4)	(3.8)	(5.1)	(4.5)
WW Operational	9.5%	5.5%	12.8%	8.2%
U.S.	8.6%	7.6%	15.5%	10.0%
International	10.1%	3.1%	10.3%	6.5%
Abiomed			(4.7)	(1.4)
U.S.			(8.2)	(2.3)
International			(1.6)	(0.5)
All Other Acquisitions and Divestitures	0.0	0.1	0.0	0.1
U.S.	0.0	0.0	0.0	0.0
International	0.0	0.3	0.0	0.2
WW Adjusted Operational	9.5%	5.6%	8.1%	6.9%
U.S.	8.6%	7.6%	7.3%	7.7%
International	10.1%	3.4%	8.7%	6.2%

Note: Percentages are based on actual, non-rounded figures and may not sum